Johnson & Johnson

Johnson & Johnson trades near the top of its 52-week range at $263.1, with a P/E of 30.09. The Alpha Score of 62.4 is driven by momentum at 91.4, but value scores just 39.1. Revenue grew 7.9% year over year, yet EPS fell 3.9%, a divergence that keeps the quality score at 60.9 and sentiment at 50. Net margin of 21.8% remains solid. The stock's high multiple reflects the momentum bid, not earnings expansion. Watch next quarter's revenue growth rate and whether EPS can stabilize after the decline.

Johnson & Johnson sits near the top of its 52-week range at $263.1, a level that reflects the momentum score of 98.3 in the Alpha model. That reading is the standout: value scores just 39.1, and the P/E of 30.09 is well above the sector median. Revenue grew 7.9% year over year, but EPS fell 3.9%, a divergence that the quality score of 60.9 captures. Net margin held at 21.8%, a stable figure. The next quarterly report will test whether revenue growth can sustain the current multiple.

Johnson & Johnson slipped another 0.7% Friday, extending a week-long slide that has the stock testing the lower end of its recent range. The P/E sits at 30x trailing earnings, which looks stretched for a company with flat EPS growth year-over-year. Revenue rose 7.9%, but the bottom line contracted 3.9%, pinching the net margin to 21.8%. The Alpha Score tells the story: momentum at 99.4 is near-perfect, but value scores 39.1 and quality 60.9. That split explains the indecision. Traders are paying up for the revenue trajectory while questioning whether margins can hold. The 52-week range of $154 to $263 leaves plenty of room, but the stock has not touched the highs since mid-2023. Next week's focus is the August healthcare conference circuit. No JNJ-specific catalysts on the calendar, but sector-wide commentary on drug pricing and patent cliffs could shift sentiment. The value score needs to climb above 50 before the stock can sustain a breakout.

Johnson & Johnson drifted lower Friday, trading near the middle of its $151-$255 range. The stock carries a P/E of 29.14 on trailing earnings of $8.65 a share, a premium that reflects the steady margin profile more than growth. Revenue advanced 7.9% year over year, but EPS declined 3.9% over the same stretch. That divergence shows up in the Alpha Score: momentum at 99.4, value at 41.2. Quality scores a respectable 60.9, aided by the 21.8% net margin. Sentiment sits right at the midpoint. Next week brings the quarterly ex-dividend date. The payout has been a consistent floor for the stock in past years, and with the 52-week low still 42% below current levels, income buyers may provide support in a defensive rotation.

Johnson & Johnson paid $30 million upfront for Nanobiotix's tumor-injected radiation enhancer. The Phase 3 sarcoma readout arrives in the second half of 2025, a binary catalyst for the partnership. JNJ's Alpha Score sits at 60.4, with momentum scoring 80 but value at 44.7. The stock's net margin of 21.8% reflects the high-margin pharma model, but EPS fell 3.9% year over year even as revenue rose 7.9%. The company trades at 26 times earnings, above the sector median, partly justified by its quality score of 60.9. Sentiment is neutral at 50. Watch the second half of 2025: the Nanobiotix readout will either validate a new radiotherapy platform or reset expectations for the pipeline.